NCT00990015 - A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Healthy Volunteers

Interventions

DRUG

PF-04308515

Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.

DRUG

Placebo

Placebo solution/suspension to match active drug QD at a single dose.

Trial Locations (1)

Pfizer Investigational Site, New Haven